IDEXX Laboratories, Inc. $IDXX Stake Increased by International Assets Investment Management LLC

International Assets Investment Management LLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 30,484.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 234,274 shares of the company’s stock after acquiring an additional 233,508 shares during the quarter. IDEXX Laboratories comprises approximately 0.9% of International Assets Investment Management LLC’s investment portfolio, making the stock its 15th biggest position. International Assets Investment Management LLC’s holdings in IDEXX Laboratories were worth $122,336,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Aurora Investment Managers LLC. acquired a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $2,442,000. National Pension Service increased its position in IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after purchasing an additional 6,885 shares during the last quarter. NewEdge Advisors LLC increased its position in IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after purchasing an additional 5,761 shares during the last quarter. Arizona State Retirement System boosted its holdings in IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after purchasing an additional 1,074 shares during the last quarter. Finally, Howard Capital Management LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at about $1,249,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several analyst reports. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday. They set a “buy” rating on the stock. Leerink Partners decreased their price objective on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Barclays lowered their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, KeyCorp assumed coverage on IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating for the company. Eight equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $721.67.

IDEXX Laboratories Trading Down 4.3%

NASDAQ IDXX opened at $551.21 on Friday. The firm’s 50-day moving average is $534.27 and its two-hundred day moving average is $574.09. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock has a market capitalization of $43.42 billion, a P/E ratio of 38.76 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter last year, the firm posted $3.50 earnings per share. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.